Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In relation to the lipodystrophy syndrome, it appears that the most powerful determinant of subcutaneous fat wasting is an interaction between these two drug classes. In this review, possible mechanisms underlying the contributions of both PI and NRTI drugs are reviewed, with an emphasis on their effects on adipose tissue. On this basis, an 'adipocentric', or minimal model of the syndrome is developed, in which divergent effects at the adipocyte of NRTIs (mitochondrial toxicity) and PIs (insulin resistance and impaired adipocyte maturation) interact to produce a phenotype that is consistent with clinical observations.
Nolan
D
D
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia.
John
M
M
Mallal
S
S
D017667:Adipocytes / Q000187:drug effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D008928:Mitochondria / Q000187:drug effects; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors